10-Q quarterly report · filed Oct 29, 2026

PTC THERAPEUTICS, INC. (PTCT) Q3 2026 10-Q Quarterly Report

Short answer

PTC THERAPEUTICS, INC. (PTCT) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $358M (up 69.6% year over year) with net income of −$52M.

Q3 2026 key financials · XBRL

Revenue
$358M
+69.6% YoY · −0.8% QoQ
Net income
−$52M
−425.2% YoY · −161.9% QoQ
Operating margin
7.0%
EPS (diluted)
−$0.56
−450.0% YoY · −160.2% QoQ

Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) Q3 2026 10-Q on SEC EDGAR. USD.

PTC THERAPEUTICS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $357.8M, up from $210.2M YoY, driven by Sephience and Evrysdi royalties
  • Sephience best performer: $181.9M sales vs $19.6M YoY; Emflaza worst, $25.1M vs $35.2M
  • Net loss $0.1M implied by reported data, versus $0.1M net income YoY; no margin percentages disclosed
  • Cash, equivalents and marketable securities $2.13B; operating cash flow $44.8M vs $745.5M
  • $535.4M convertible-note proceeds, $328.8M used for 2026 note repurchases; headwinds from Emflaza generics and Translarna access risks

Risk Factors

  • New regulatory risk: ST-920 acquisition adds FDA accelerated-approval uncertainty, with rolling BLA completion expected in fourth quarter 2026
  • Most material update: Translarna U.S. development discontinued after NDA withdrawal in February 2026, while EEA authorization remains affected by the EC negative opinion
  • Regulatory compliance risk: vatiquinone requires an additional controlled study after FDA’s August 2025 complete response letter
  • Operational risk: three distributors each exceeded the undisclosed concentration threshold for net product sales in 2026
  • Financial risk: $550.0 million 2031 Convertible Notes mature June 15, 2031, alongside $2,305.6 million royalty-sale liability carrying an 11.0% effective rate

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PTC THERAPEUTICS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.